Filter News

Astellas Oncology Announces Data To Be Presented At 2016 ASCO Annual Meeting

Published: May 19, 2016

NORTHBROOK, Ill., May 19, 2016 /PRNewswire/ -- Astellas announced today a selection of abstracts it will present on early phase data for ASP8273 in patients with EGFR mutation positive non-small cell lung cancer (NCSLC), gilteritinib pharmacokinetics and pharmacodynamics in patients with relapsed or refractory acute myeloid leukemia and two investigational antibody drug conjugates in patients with metastatic urothelial cancer at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7 in Chicago.

Astellas is a pharmaceutical company dedicated to improving the health of people around the world.

"Our activity at this year's ASCO annual meeting underscores our immense commitment to helping those living with cancer," said Stephen Eck, M.D., vice president and interim head of global oncology development, Astellas. "Building on our foundation in non-small cell lung, pancreatic and advanced prostate cancers, we are continuously focused on identifying innovative ways to address the unmet needs of patients and caregivers facing cancer every day."

The following are a selection of abstracts that will be presented during poster sessions:

Title: (9050) Antitumor Activity of ASP8273 300mg in Subjects with EGFR Mutation-Positive Non-Small Cell Lung Cancer: Interim Results from an Ongoing Phase 1 Study.

Presenter: Helena Alexandra Yu, M.D., Memorial Sloan Kettering Cancer Center

  • Session Date/Time: Saturday, June 4, 8:00-11:30 a.m. CDT
  • Location: Hall A

Title: (7026) Pharmacokinetics and pharmacodynamics of gilteritinib in patients with relapsed or refractory acute myeloid leukemia.

Presenter: Catherine Choy Smith, M.D., University of California San Francisco

  • Session Date/Time: Monday, June 6, 8:00-11:30 a.m. CDT
  • Location: Hall A

Title: (4532) Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of AGS15E (ASG-15ME) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC)

Presenter: Daniel Peter Petrylak, M.D., Yale University

  • Session Date/Time: Monday, June 6, 1:004:30 p.m. CDT
  • Location: Hall A

Title: (4533) Anti-Tumor Activity, Safety and Pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a Phase I Dose Escalation Trial in Patients (Pts) with Metastatic Urothelial Cancer (mUC)

Presenter: Jonathan E. Rosenberg, M.D., Memorial Sloan Kettering Cancer Center

  • Session Date/Time: Monday, June 6, 1:004:30 p.m. CDT
  • Location: Hall A

AGS15E and ASG-22CE are being co-developed under a collaboration with Seattle Genetics.

About Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.

Logo - http://photos.prnewswire.com/prnh/20140416/84970

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-oncology-announces-data-to-be-presented-at-2016-asco-annual-meeting-300271500.html

SOURCE Astellas Pharma Inc.

Back to news